These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 22509934)

  • 61. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats.
    Feldmann A; Stamova S; Bippes CC; Bartsch H; Wehner R; Schmitz M; Temme A; Cartellieri M; Bachmann M
    Prostate; 2011 Jun; 71(9):998-1011. PubMed ID: 21541976
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Construction and functional analysis of an anti-human cervical carcinoma/anti-human CD3 single-chain bispecific antibody.
    Wu H; Yao L; Chou L; Yang JH; Zhang YX; Li XL; Shan BE
    Mol Med Rep; 2016 Jul; 14(1):804-10. PubMed ID: 27220396
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.
    Smith EJ; Olson K; Haber LJ; Varghese B; Duramad P; Tustian AD; Oyejide A; Kirshner JR; Canova L; Menon J; Principio J; MacDonald D; Kantrowitz J; Papadopoulos N; Stahl N; Yancopoulos GD; Thurston G; Davis S
    Sci Rep; 2015 Dec; 5():17943. PubMed ID: 26659273
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells.
    Torisu-Itakura H; Schoellhammer HF; Sim MS; Irie RF; Hausmann S; Raum T; Baeuerle PA; Morton DL
    J Immunother; 2011 Oct; 34(8):597-605. PubMed ID: 21904216
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Selection for Anti-transferrin Receptor Bispecific T-cell Engager in Different Molecular Formats.
    Fu MP; Guo ZL; Tang HL; Zhu HF; Shen GX; He Y; Lei P
    Curr Med Sci; 2020 Feb; 40(1):28-34. PubMed ID: 32166662
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of different interchain linkers on biological activity of an anti-prostate cancer single-chain bispecific antibody.
    Hao CH; Han QH; Shan ZJ; Hu JT; Zhang N; Zhang XP
    Theor Biol Med Model; 2015 Aug; 12():14. PubMed ID: 26246000
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
    Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M
    MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Generation and characterization of a bispecific diabody targeting both EPH receptor A10 and CD3.
    Kamada H; Taki S; Nagano K; Inoue M; Ando D; Mukai Y; Higashisaka K; Yoshioka Y; Tsutsumi Y; Tsunoda S
    Biochem Biophys Res Commun; 2015 Jan; 456(4):908-12. PubMed ID: 25528586
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bispecific Antibody Armed T Cells to Target Cancer Cells.
    Thakur A; Lum LG; Mittal S
    Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours.
    Huang MTF; Sharma V; Mendelsohn A; Wei Q; Li J; Yu B; Larrick JW; Lum LG
    Ann Med; 2022 Dec; 54(1):1047-1057. PubMed ID: 36799362
    [No Abstract]   [Full Text] [Related]  

  • 71. Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice.
    Davol PA; Smith JA; Kouttab N; Elfenbein GJ; Lum LG
    Clin Prostate Cancer; 2004 Sep; 3(2):112-21. PubMed ID: 15479495
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Construction and expression of anti-CD3/anti-prostate-cancer bispecific single-chain antibody].
    Wang D; Wu GJ; Wang H; Yang SL; Wu WZ; Xu TZ; Tan JM
    Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(15):1292-5. PubMed ID: 12930679
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing.
    Ross SL; Sherman M; McElroy PL; Lofgren JA; Moody G; Baeuerle PA; Coxon A; Arvedson T
    PLoS One; 2017; 12(8):e0183390. PubMed ID: 28837681
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibition of Intercellular Communication between Prostate Cancer Cells by A Specific Anti-STEAP-1 Single Chain Antibody.
    Esmaeili SA; Nejatollahi F; Sahebkar A
    Anticancer Agents Med Chem; 2018; 18(12):1674-1679. PubMed ID: 29219059
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy.
    Xie F; Zhang L; Shi S; Zheng A; Di J; Jin S; Miao X; Wu F; Chen X; Zhang Y; Wei X; Xu Y
    MAbs; 2022; 14(1):2115205. PubMed ID: 36041060
    [TBL] [Abstract][Full Text] [Related]  

  • 76. ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.
    Chervin AS; Stone JD; Konieczna I; Calabrese KM; Wang N; Haribhai D; Dong F; White MK; Rodriguez LE; Bukofzer GT; Ellis PA; Cosgrove C; Hecquet C; Clarin JD; Palma JP; Reilly EB
    Mol Cancer Ther; 2023 Aug; 22(8):903-912. PubMed ID: 37294945
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.
    Aschmoneit N; Kühl L; Seifert O; Kontermann RE
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782429
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy.
    McCue AC; Demarest SJ; Froning KJ; Hickey MJ; Antonysamy S; Kuhlman B
    MAbs; 2024; 16(1):2373325. PubMed ID: 38962811
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells.
    Aschmoneit N; Steinlein S; Kühl L; Seifert O; Kontermann RE
    Sci Rep; 2021 Jul; 11(1):13880. PubMed ID: 34230555
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager.
    Bi Y; Jiang H; Wang P; Song B; Wang H; Kong X; Li Z
    Oncotarget; 2017 Aug; 8(32):52866-52876. PubMed ID: 28881778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.